Selective MAO-B inhibitors, such as Selegiline and Rasagiline, show symptomatic benefit in early-stage PD, reducing motor deficits and levodopa requirements without increasing morbidity or mortality [8]. The gene discussed is MAOB; the disease is Parkinson disease.